Full Press Release Details
CureVac Announces Voting Results of Extraordinary
T BINGEN, Germany / BOSTON, USA - March 28, 2023
- CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger
ribonucleic acid ("mRNA"), today announced the voting results of the Company's extraordinary general meeting.
The shareholders of the Company voted in favor of all proposals. The
proposals were for the appointments of Dr. Alexander Zehnder and Myriam Mendila as managing directors.
A table containing tabulations of the votes casted is expected to be
released in the coming days.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020,
CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on
CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T bingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate
Communications and Investor Relations
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
CureVac Media Relations Contact
Bettina J dicke-Braas, Manager Communications
CureVac, T bingen, Germany
T +49 7071 9883-1087
Forward-Looking Statements CureVac
This press release contains statements that constitute
"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or
its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH,
CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future
results, in contrast with statements that reflect historical facts. In some cases, you can identify such forward-looking statements by
terminology such as "anticipate," "intend," "believe," "estimate," "plan,"
"seek," "project," or "expect," "may," "will," "would," "could,"
"potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide
economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct
current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third
parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current
and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's
industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance
on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results
due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could
cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press
release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such
statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except
For further information, please reference the company's reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC
website at www.sec.gov.